The gene therapy approach has largely been improved by the development of new methods in gene transfer and genome editing. The use of CART cells was first approved in 2018 by FDA for ex vivo treatment of B cell acute lymphoblastic leukemia and in vivo treatment of retinal dystrophy. This revolutionary trend is expected to continue as the clinical vision develops and the technical capacity improves.